Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyRizatriptan
Identification
- Name
- Rizatriptan
- Accession Number
- DB00953 (APRD00008)
- Type
- Small Molecule
- Groups
- Approved
- Description
Rizatriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.
- Structure
Structure for Rizatriptan (DB00953)
- Synonyms
- N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine
- N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine
- Risatriptan
- Rizatriptán
- Rizatriptan
- Rizatriptanum
- External IDs
- L-705126 / MK 462 Free Base / MK-462 FREE BASE
- Product Ingredients
Ingredient UNII CAS InChI Key Rizatriptan benzoate WR978S7QHH 145202-66-0 JPRXYLQNJJVCMZ-UHFFFAOYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Act Rizatriptan Tablet 10 mg Oral Actavis Pharma Company 2012-06-14 Not applicable Canada 
Act Rizatriptan Tablet 5 mg Oral Actavis Pharma Company Not applicable Not applicable Canada Act Rizatriptan ODT Tablet, orally disintegrating 10 mg Oral Actavis Pharma Company 2012-01-30 Not applicable Canada Act Rizatriptan ODT Tablet, orally disintegrating 5 mg Oral Actavis Pharma Company 2012-01-30 Not applicable Canada Maxalt Tablet 10 mg/1 Oral Stat Rx USA 1998-06-29 Not applicable US 
Maxalt Tablet 5 mg/1 Oral Merck Sharp & Dohme Corp. 1998-06-29 Not applicable US Maxalt Tablet 5 mg Oral Merck Ltd. 1999-08-31 2013-07-15 Canada Maxalt Tablet 10 mg/1 Oral Rebel Distributors 1998-06-29 Not applicable US Maxalt Tablet 10 mg Oral Merck Ltd. 1999-08-31 Not applicable Canada Maxalt Tablet 10 mg/1 Oral Lake Erie Medical Dba Quality Care Produts Llc 2007-08-24 2014-12-31 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-rizatriptan Tablet 10 mg Oral Apotex Corporation 2012-09-27 Not applicable Canada Apo-rizatriptan Tablet 5 mg Oral Apotex Corporation 2013-03-06 Not applicable Canada Apo-rizatriptan Rpd Tablet, orally disintegrating 5 mg Oral Apotex Corporation 2013-09-10 Not applicable Canada Apo-rizatriptan Rpd Tablet, orally disintegrating 10 mg Oral Apotex Corporation 2013-09-10 Not applicable Canada Auro-rizatriptan Tablet 10 mg Oral Auro Pharma Inc 2016-04-12 Not applicable Canada Auro-rizatriptan ODT Tablet, orally disintegrating 10 mg Oral Auro Pharma Inc Not applicable Not applicable Canada Auro-rizatriptan ODT Tablet, orally disintegrating 5 mg Oral Auro Pharma Inc Not applicable Not applicable Canada Ccp-rizatriptan ODT Tablet, orally disintegrating 5 mg Oral Cellchem Pharmaceuticals Inc. Not applicable Not applicable Canada Ccp-rizatriptan ODT Tablet, orally disintegrating 10 mg Oral Cellchem Pharmaceuticals Inc. Not applicable Not applicable Canada Dom-rizatriptan Rdt Tablet, orally disintegrating 10 mg Oral Dominion Pharmacal 2013-05-20 Not applicable Canada - International/Other Brands
- Maxalt MLT
- Categories
- Agents that produce hypertension
- Amines
- Analgesics
- Antimigraine Preparations
- Biogenic Amines
- Biogenic Monoamines
- Central Nervous System Depressants
- Indoles
- Migraine Disorders
- Nervous System
- Neurotransmitter Agents
- Selective Serotonin 5-HT1 Receptor Agonists
- Selective Serotonin Agonists
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin 1b Receptor Agonists
- Serotonin 1d Receptor Agonists
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Agents
- Serotonin Modulators
- Serotonin Receptor Agonists
- Serotonin-1b and Serotonin-1d Receptor Agonist
- Triptans
- UNII
- 51086HBW8G
- CAS number
- 144034-80-0
- Weight
- Average: 269.3449
Monoisotopic: 269.164045633 - Chemical Formula
- C15H19N5
- InChI Key
- ULFRLSNUDGIQQP-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
- IUPAC Name
- dimethyl({2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethyl})amine
- SMILES
- CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
Pharmacology
- Indication
For treatment of acute migraine attacks with or without aura.
- Associated Conditions
- Pharmacodynamics
Rizatriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists and has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Rizatriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Rizatriptan in humans.
- Mechanism of action
Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
Target Actions Organism A5-hydroxytryptamine receptor 1D agonistHumans A5-hydroxytryptamine receptor 1B agonistHumans A5-hydroxytryptamine receptor 1F agonistHumans - Absorption
Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.
- Volume of distribution
- 140 L [male]
- 110 L [female]
- Protein binding
14%
- Metabolism
Rizatriptan is metabolized by monoamine oxidase A isoenzyme (MAO-A) to an inactive indole acetic acid metabolite. In addition, several other inactive metabolites are formed. An active metabolite, N-monodesmethyl-rizatriptan, with pharmacological activity similar to that of the parent compound has been identified in small concentrations (14%) in the plasma.
- Route of elimination
Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism.
- Half life
2-3 hours
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 --- (C;T) / (T;T) T Allele Effect Directly Studied Patients with this genotype have an increased likelihood of responding to rizatriptan when treating (condition: cluster headache). Details
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin The risk or severity of adverse effects can be increased when Rizatriptan is combined with (R)-warfarin. (S)-Warfarin The risk or severity of adverse effects can be increased when Rizatriptan is combined with (S)-Warfarin. 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of hypertension can be increased when Rizatriptan is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid. 1-benzylimidazole The risk or severity of hypertension can be increased when Rizatriptan is combined with 1-benzylimidazole. 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of serotonin syndrome can be increased when Rizatriptan is combined with 2,5-Dimethoxy-4-ethylamphetamine. 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of serotonin syndrome can be increased when Rizatriptan is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. 3,4-Methylenedioxyamphetamine The risk or severity of serotonin syndrome can be increased when Rizatriptan is combined with 3,4-Methylenedioxyamphetamine. 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of serotonin syndrome can be increased when Rizatriptan is combined with 4-Bromo-2,5-dimethoxyamphetamine. 4-hydroxycoumarin The risk or severity of adverse effects can be increased when Rizatriptan is combined with 4-hydroxycoumarin. 4-Methoxyamphetamine The metabolism of Rizatriptan can be decreased when combined with 4-Methoxyamphetamine. - Food Interactions
- Not Available
References
- Synthesis Reference
Montserrat Armengol Asparo, Pere Dalmases Barjoan, "Process for preparing a rizatriptan." U.S. Patent US20050148778, issued July 07, 2005.
US20050148778- General References
- Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. [PubMed:12093318]
- Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. [PubMed:12269863]
- Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. [PubMed:15056946]
- Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. [PubMed:12434581]
- Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011]
- External Links
- Human Metabolome Database
- HMDB0015088
- KEGG Drug
- D00675
- PubChem Compound
- 5078
- PubChem Substance
- 46506557
- ChemSpider
- 4900
- BindingDB
- 50033437
- ChEBI
- 48273
- ChEMBL
- CHEMBL905
- Therapeutic Targets Database
- DAP000220
- PharmGKB
- PA451264
- IUPHAR
- 51
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Rizatriptan
- ATC Codes
- N02CC04 — Rizatriptan
- AHFS Codes
- 28:32.28 — Selective Serotonin Agonists
- FDA label
- Download (873 KB)
- MSDS
- Download (57.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Migraine Disorders 1 2 Completed Treatment Migraines 1 2, 3 Recruiting Treatment Migrainous Vertigo / Vestibular Migraine 1 3 Completed Treatment Acute Migraine With or Without Aura in Adolescents 1 3 Completed Treatment Migraine Disorders 1 3 Completed Treatment Migraine, Acute 2 3 Completed Treatment Migraines 4 3 Completed Treatment Migrainous Headache 4 4 Completed Basic Science Episodic Migraine 1 4 Completed Treatment Migraines 3 4 Completed Treatment Migrainous Headache 1 Not Available Completed Basic Science Migraines 1 Not Available Withdrawn Treatment Chronic Post-traumatic Headache 1
Pharmacoeconomics
- Manufacturers
- Merck and co inc
- Packagers
- Catalent Pharma Solutions
- Chunghwa Chemical Synthesis and Biotech Co. Ltd.
- Diversified Healthcare Services Inc.
- Lake Erie Medical and Surgical Supply
- Merck & Co.
- Nucare Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Scherer Drug Delivery Systems Ltd.
- Dosage forms
Form Route Strength Tablet Oral 5 mg Tablet Oral 10 mg/1 Tablet Oral 10 mg Tablet, orally disintegrating Oral 10 mg Tablet, orally disintegrating Oral 5 mg Tablet, orally disintegrating Oral 10 mg/1 Tablet, orally disintegrating Oral 5 mg/1 Tablet, film coated Oral 10 mg/1 Tablet, film coated Oral 5 mg/1 Tablet Oral 5 mg/1 - Prices
Unit description Cost Unit Maxalt 12 10 mg tablet Box 333.27USD box Maxalt 12 5 mg tablet Box 333.27USD box Maxalt-MLT 3 5 mg Dispersible Tablet Box 286.96USD box Maxalt 9 5 mg tablet Box 203.46USD box Maxalt 6 5 mg tablet Box 107.44USD box Maxalt-MLT 3 10 mg Dispersible Tablet Box 83.32USD box Maxalt mlt 10 mg tablet 26.7USD tablet Maxalt mlt 5 mg tablet 26.7USD tablet Maxalt 10 mg tablet 25.31USD tablet Maxalt 5 mg tablet 22.98USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5602162 No 1997-02-11 2014-02-11 US US5298520 No 1994-03-29 2012-06-29 US CA2060139 No 1998-12-01 2012-01-28 Canada
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 178-180 °C Not Available water solubility 42 mg/mL (for free base) Not Available logP 1.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.338 mg/mL ALOGPS logP 1.67 ALOGPS logP 1.77 ChemAxon logS -2.9 ALOGPS pKa (Strongest Acidic) 17.24 ChemAxon pKa (Strongest Basic) 9.56 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 49.74 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 93.13 m3·mol-1 ChemAxon Polarizability 30 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9406 Caco-2 permeable + 0.5547 P-glycoprotein substrate Substrate 0.7478 P-glycoprotein inhibitor I Non-inhibitor 0.8752 P-glycoprotein inhibitor II Non-inhibitor 0.7244 Renal organic cation transporter Inhibitor 0.7394 CYP450 2C9 substrate Non-substrate 0.8572 CYP450 2D6 substrate Non-substrate 0.6765 CYP450 3A4 substrate Substrate 0.5574 CYP450 1A2 substrate Non-inhibitor 0.9149 CYP450 2C9 inhibitor Non-inhibitor 0.9063 CYP450 2D6 inhibitor Non-inhibitor 0.8913 CYP450 2C19 inhibitor Non-inhibitor 0.9515 CYP450 3A4 inhibitor Non-inhibitor 0.9688 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.956 Ames test AMES toxic 0.5644 Carcinogenicity Non-carcinogens 0.9133 Biodegradation Not ready biodegradable 0.9439 Rat acute toxicity 2.5433 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7051 hERG inhibition (predictor II) Non-inhibitor 0.7265
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0udi-0590000000-de0b61f549c5a86c98df
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Tryptamines and derivatives
- Direct Parent
- Tryptamines and derivatives
- Alternative Parents
- 3-alkylindoles / Aralkylamines / Substituted pyrroles / Benzenoids / Triazoles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Tryptamine / 3-alkylindole / Indole / Aralkylamine / Substituted pyrrole / Benzenoid / Azole / Pyrrole / 1,2,4-triazole / Heteroaromatic compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- tryptamines (CHEBI:48273)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
- Gene Name
- HTR1D
- Uniprot ID
- P28221
- Uniprot Name
- 5-hydroxytryptamine receptor 1D
- Molecular Weight
- 41906.38 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A, Schofield WN, Taylor AA, Hill RG: Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol. 1997 Jan-Feb;12(1):3-9. [PubMed:9127118]
- Longmore J, Boulanger CM, Desta B, Hill RG, Schofield WN, Taylor AA: 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol. 1996 Oct;42(4):431-41. [PubMed:8904614]
- Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T: Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol. 1997 Jan;43(1):49-54. [PubMed:9056052]
- Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ: The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. [PubMed:11487512]
- Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. [PubMed:15821444]
- Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. [PubMed:12093318]
- Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. [PubMed:12269863]
- Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. [PubMed:15056946]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
- Gene Name
- HTR1B
- Uniprot ID
- P28222
- Uniprot Name
- 5-hydroxytryptamine receptor 1B
- Molecular Weight
- 43567.535 Da
References
- Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. [PubMed:12093318]
- Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. [PubMed:12269863]
- Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. [PubMed:15056946]
- Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. [PubMed:9650800]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ: The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34. [PubMed:11487512]
- Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. [PubMed:15821444]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
- Gene Name
- HTR1F
- Uniprot ID
- P30939
- Uniprot Name
- 5-hydroxytryptamine receptor 1F
- Molecular Weight
- 41708.505 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. [PubMed:15320857]
- Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. [PubMed:12434581]
- Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL: Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol. 1998 Jul 3;352(1):117-24. [PubMed:9718276]
- Goadsby PJ, Classey JD: Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. [PubMed:14614913]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Serotonin binding
- Specific Function
- Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
- Gene Name
- MAOA
- Uniprot ID
- P21397
- Uniprot Name
- Amine oxidase [flavin-containing] A
- Molecular Weight
- 59681.27 Da
References
- Iwasa T, Sano H, Sugiura A, Uchiyama N, Hara K, Okochi H, Nakagawa K, Yasumori T, Ishizaki T: An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug. Br J Clin Pharmacol. 2003 Nov;56(5):537-44. [PubMed:14651728]
- Van Haarst AD, Van Gerven JM, Cohen AF, De Smet M, Sterrett A, Birk KL, Fisher AL, De Puy ME, Goldberg MR, Musson DG: The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol. 1999 Aug;48(2):190-6. [PubMed:10417495]
- Med-Psych Drug-Drug Interactions Update: Triptans [File]
Drug created on June 13, 2005 07:24 / Updated on January 22, 2019 17:56